Bcl‐2/Bcl‐xL inhibition predominantly synergistically enhances the anti‐neoplastic activity of a low‐dose CUSP9 repurposed drug regime against glioblastoma
Published 2019 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Bcl‐2/Bcl‐xL inhibition predominantly synergistically enhances the anti‐neoplastic activity of a low‐dose CUSP9 repurposed drug regime against glioblastoma
Authors
Keywords
-
Journal
BRITISH JOURNAL OF PHARMACOLOGY
Volume -, Issue -, Pages -
Publisher
Wiley
Online
2019-06-21
DOI
10.1111/bph.14773
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Experimental design and analysis and their reporting II: updated and simplified guidance for authors and peer reviewers
- (2018) Michael J Curtis et al. BRITISH JOURNAL OF PHARMACOLOGY
- Repurposing drugs for glioblastoma: From bench to bedside
- (2018) João Basso et al. CANCER LETTERS
- Drug Repurposing of Metabolic Agents in Malignant Glioma
- (2018) Corinna Seliger et al. INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
- Targeting intrinsic apoptosis and other forms of cell death by BH3-mimetics in glioblastoma
- (2017) Georg Karpel-Massler et al. Expert Opinion on Drug Discovery
- Convection-enhanced delivery in glioblastoma: a review of preclinical and clinical studies
- (2017) Arman Jahangiri et al. JOURNAL OF NEUROSURGERY
- Anti-glioma Activity of Dapsone and Its Enhancement by Synthetic Chemical Modification
- (2017) Georg Karpel-Massler et al. NEUROCHEMICAL RESEARCH
- The IUPHAR/BPS Guide to PHARMACOLOGY in 2018: updates and expansion to encompass the new guide to IMMUNOPHARMACOLOGY
- (2017) Simon D Harding et al. NUCLEIC ACIDS RESEARCH
- Induction of synthetic lethality in IDH1-mutated gliomas through inhibition of Bcl-xL
- (2017) Georg Karpel-Massler et al. Nature Communications
- A Synthetic Cell-Penetrating Dominant-Negative ATF5 Peptide Exerts Anticancer Activity against a Broad Spectrum of Treatment-Resistant Cancers
- (2016) G. Karpel-Massler et al. CLINICAL CANCER RESEARCH
- Metabolic reprogramming of glioblastoma cells by L-asparaginase sensitizes for apoptosis in vitro and in vivo
- (2016) Georg Karpel-Massler et al. Oncotarget
- Inhibition of deubiquitinases primes glioblastoma cells to apoptosis in vitro and in vivo
- (2016) Georg Karpel-Massler et al. Oncotarget
- Phase 1 study of the safety, pharmacokinetics, and antitumour activity of the BCL2 inhibitor navitoclax in combination with rituximab in patients with relapsed or refractory CD20+lymphoid malignancies
- (2015) Andrew W. Roberts et al. BRITISH JOURNAL OF HAEMATOLOGY
- Safety, efficacy, and pharmacokinetics of navitoclax (ABT-263) in combination with erlotinib in patients with advanced solid tumors
- (2015) Anthony W. Tolcher et al. CANCER CHEMOTHERAPY AND PHARMACOLOGY
- A paired comparison between glioblastoma “stem cells” and differentiated cells
- (2015) Matthias Schneider et al. INTERNATIONAL JOURNAL OF CANCER
- A phase 2 study of the BH3 mimetic BCL2 inhibitor navitoclax (ABT-263) with or without rituximab, in previously untreated B-cell chronic lymphocytic leukemia
- (2015) Thomas J. Kipps et al. LEUKEMIA & LYMPHOMA
- TIC10/ONC201 synergizes with Bcl-2/Bcl-xL inhibition in glioblastoma by suppression of Mcl-1 and its binding partners in vitro and in vivo
- (2015) Georg Karpel-Massler et al. Oncotarget
- A Potential Role for the Inhibition of PI3K Signaling in Glioblastoma Therapy
- (2015) Stephanie Ströbele et al. PLoS One
- COX-2-Independent Effects of Celecoxib Sensitize Lymphoma B Cells to TRAIL-Mediated Apoptosis
- (2014) A.-S. Gallouet et al. CLINICAL CANCER RESEARCH
- Olanzapine inhibits proliferation, migration and anchorage-independent growth in human glioblastoma cell lines and enhances temozolomide’s antiproliferative effect
- (2014) Georg Karpel-Massler et al. JOURNAL OF NEURO-ONCOLOGY
- A Randomized Trial of Bevacizumab for Newly Diagnosed Glioblastoma
- (2014) Mark R. Gilbert et al. NEW ENGLAND JOURNAL OF MEDICINE
- Bevacizumab plus Radiotherapy–Temozolomide for Newly Diagnosed Glioblastoma
- (2014) Olivier L. Chinot et al. NEW ENGLAND JOURNAL OF MEDICINE
- PARP Inhibition Restores Extrinsic Apoptotic Sensitivity in Glioblastoma
- (2014) Georg Karpel-Massler et al. PLoS One
- Single-cell RNA-seq highlights intratumoral heterogeneity in primary glioblastoma
- (2014) A. P. Patel et al. SCIENCE
- Enhanced apoptotic effects by downregulating Mcl-1: Evidence for the improvement of photodynamic therapy with Celecoxib
- (2013) Jiaxing Song et al. EXPERIMENTAL CELL RESEARCH
- Combined Inhibition of HER1/EGFR and RAC1 Results in a Synergistic Antiproliferative Effect on Established and Primary Cultured Human Glioblastoma Cells
- (2013) G. Karpel-Massler et al. MOLECULAR CANCER THERAPEUTICS
- Phase II Study of Single-Agent Navitoclax (ABT-263) and Biomarker Correlates in Patients with Relapsed Small Cell Lung Cancer
- (2012) C. M. Rudin et al. CLINICAL CANCER RESEARCH
- Navitoclax, a targeted high-affinity inhibitor of BCL-2, in lymphoid malignancies: a phase 1 dose-escalation study of safety, pharmacokinetics, pharmacodynamics, and antitumour activity
- (2010) Wyndham H Wilson et al. LANCET ONCOLOGY
- Phase III randomized trial of CED of IL13-PE38QQR vs Gliadel wafers for recurrent glioblastoma
- (2010) S. Kunwar et al. NEURO-ONCOLOGY
- Randomized Phase II Trial of Erlotinib Versus Temozolomide or Carmustine in Recurrent Glioblastoma: EORTC Brain Tumor Group Study 26034
- (2009) Martin J. van den Bent et al. JOURNAL OF CLINICAL ONCOLOGY
- ABT-263: A Potent and Orally Bioavailable Bcl-2 Family Inhibitor
- (2008) C. Tse et al. CANCER RESEARCH
- Phosphatidylinositol 3-Kinase Inhibition Broadly Sensitizes Glioblastoma Cells to Death Receptor- and Drug-Induced Apoptosis
- (2008) D. Opel et al. CANCER RESEARCH
Discover Peeref hubs
Discuss science. Find collaborators. Network.
Join a conversationCreate your own webinar
Interested in hosting your own webinar? Check the schedule and propose your idea to the Peeref Content Team.
Create Now